Robey, R. W., Fitzsimmons, C. M., Guiblet, W. M., Frye, W. J. E., González Dalmasy, J. M., Wang, L., Russell, D. A., Huff, L. M., Perciaccante, A. J., Ali-Rahmani, F., Lipsey, C. C., Wade, H. M., Mitchell, A. V., Maligireddy, S. S., Terrero, D., Butcher, D., Edmondson, E. F., Jenkins, L. M., Nikitina, T., … Batista, P. J. (2023). The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. Molecular Cancer Therapeutics, 23(4), 464–477. https://doi.org/10.1158/1535-7163.mct-23-0144

Ryu Tiger, Y. K., Jain, S., Barta, S. K., Tolu, S., Estrella, B., Sawas, A., Lue, J. K., Francescone, M. M., Pro, B., & Amengual, J. E. (2024). Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & Lymphoma, 65(6), 736–745. https://doi.org/10.1080/10428194.2024.2329996

Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P., Mahajan, A., Humala, N., Manier, L., Caprioli, R., Quiñones-Hinojosa, A., Casaccia, P., & Canoll, P. (2024). EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. Cells, 13(3), 219. https://doi.org/10.3390/cells13030219